Chromogranin A ELISA
- Regulatory Status
- EU: CE
- Kit size
- 12 x 8
- Method
- ELISA
- Incubation time
- 1 x 90 min, 1 x 30 min, 1 x 20 min
- Standard range
- 0 - 2500 ng/mL
- Specimen / Volumes
- 15 µL Serum, Plasma
- Substrate / isotope
- TMB 450 nm
Chromogranin A is the most important general marker for the diagnosis and clinical follow-up of neuroendocrine tumors. This marker is often elevated in patients with functionally active as well as inactive tumors. Unlike other biological markers, chromogranin A is relatively stable and largely correlates with the tumor mass
IBL International has succeeded in further optimizing the well-established chromogranin A ELISA. The new chromogranin A ELISA (RE53071) correlates perfectly with the old version (RE53971) and is characterized by the following features:
- Wider measurement range: up to 2500 ng/mL
- No sample dilution necessary
- Improved analytical sensitivity: 1.4ng/mL
- Small sample volume: 15 µL
- No hook effect up to 1,000,000 ng/mL
- Outstanding correlation with the old assay version (RE53971)
General information on chromogranin A ELISA
Chromogranin A (CgA) is a 49 kDa acidic glycoprotein consisting of 439 amino acids encoded on chromosome 14. As a member of the granin family, chromogranin A is stored in and secreted from secretory granules of endocrine and neuroendocrine cells along with their hormones and neurotransmitters. It has been demonstrated in a number of normal and neoplastic endocrine tissues. An elevated level of circulating chromogranin A was found to be a marker of tumors of neuroendocrine origin.
- As a very sensitive (83%) and highly specific (96%) marker in the evaluation of a confirmed or suspected pheochromocytoma. Drugs that are commonly used in the diagnosis and treatment of pheochromocytoma have a negligible effect on the plasma chromogranin A levels, which is a considerable advantage of chromogranin A over catecholamines for the measurement purposes.
- Verification of tumor origin. High chromogranin A levels indicate that the tumor is of neuroendocrine origin.
- Detection of endocrine tumors that secrete non-tissue-specific hormones, such as C-cell cancer negative for calcitonin and positive for chromogranin; null cell adenoma, pancreatic beta-cell tumors and parathyroid tumors.
For concrete data please consult the Instruction for Use in the download box on the top right side.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.